Literature DB >> 32214681

Angiotensin Converting Enzyme-2 (ACE2) and its Possible Roles in Hypertension, Diabetes and Cardiac Function.

Fiona J Warner1,2,2, Jodie L Guy2, Dan W Lambert2, Nigel M Hooper2, Anthony J Turner2.   

Abstract

Angiotensin converting enzyme-2 (ACE2) is a recently described homologue of the vasoactive peptidase, angiotensin converting enzyme (ACE). Like ACE, ACE2 is an integral (type I) membrane zinc metallopeptidase, which exists as an ectoenzyme. ACE2 is less widely distributed than ACE in the body, being expressed at highest concentrations in the heart, kidney and testis. ACE2 also differs from ACE in its substrate specificity, functioning exclusively as a carboxypeptidase rather than a peptidyl dipeptidase. A key role for ACE2 appears to be emerging in the conversion of angiotensin II to angiotensin (1-7), allowing it to act as a counter-balance to the actions of ACE. ACE2 has been localised to the endothelial and epithelial cells of the heart and kidney where it may have a role at the cell surface in hydrolysing bioactive peptides such as angiotensin II present in the circulation. A role for ACE2 in the metabolism of other biologically active peptides also needs to be considered. ACE2 also serendipitously appears to act as a receptor for the severe acute respiratory syndrome (SARS) coronavirus. Studies using ace2 -/- mice, and other emerging studies in vivo and in vitro, have revealed that ACE2 has important functions in cardiac regulation and diabetes. Together with its role as a SARS receptor, ACE2 is therefore likely to be an important therapeutic target in a diverse range of disease states. © Kluwer Academic Publishers 2003.

Entities:  

Keywords:  ACE2; SARS; angiotensin-converting enzyme; apelin; bradykinin; diabetes; heart; hypertension; kidney; renin-angiotensin

Year:  2003        PMID: 32214681      PMCID: PMC7088140          DOI: 10.1007/s10989-004-2387-6

Source DB:  PubMed          Journal: 


  3 in total

1.  Type 2 diabetes mellitus impaired nasal immunity and increased the risk of hyposmia in COVID-19 mild pneumonia patients.

Authors:  Yi Zhao; Yujie Liu; Fangzheng Yi; Jun Zhang; Zhaohui Xu; Yehai Liu; Ye Tao
Journal:  Int Immunopharmacol       Date:  2021-01-22       Impact factor: 5.714

2.  Statins in patients with COVID-19: a retrospective cohort study in Iranian COVID-19 patients.

Authors:  Payam Peymani; Tania Dehesh; Pooneh Mokarram; Saeid Ghavami; Farnaz Aligolighasemabadi; Mohammadamin Sadeghdoust; Katarzyna Kotfis; Mazaher Ahmadi; Parvaneh Mehrbod; Pooya Iranpour; Sanaz Dastghaib; Ahmad Nasimian; Amir Ravandi; Biniam Kidane; Naseer Ahmed; Pawan Sharma; Shahla Shojaei; Kamran Bagheri Lankarani; Andrzej Madej; Nima Rezaei; Tayyebeh Madrakian; Marek J Los; Hagar Ibrahim Labouta
Journal:  Transl Med Commun       Date:  2021-01-25

3.  Virtual Screening in Search for a Chemical Probe for Angiotensin-Converting Enzyme 2 (ACE2).

Authors:  Iryna O Kravets; Dmytro V Dudenko; Alexander E Pashenko; Tatiana A Borisova; Ganna M Tolstanova; Sergey V Ryabukhin; Dmitriy M Volochnyuk
Journal:  Molecules       Date:  2021-12-14       Impact factor: 4.411

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.